Drug intelligence / Profile preview

BR6001-1 + BR6001-2

Development stage: Discontinued
Lead developer: Boryung
Modality: Small Molecules
Administration: Oral

Overview

BR6001-1 + BR6001-2 is a **combination of two small molecule investigational drugs, BR6001-1 and BR6001-2, developed by Boryung Corp.** The primary purpose of this combination is to assess drug-drug interaction and safety in healthy adult volunteers. The therapeutic area of study is digestive system disorders, with previous research in duodenal and stomach ulcers. The combination is in Phase 1 clinical trials. The precise mechanism of action and molecular targets of either component is not publicly disclosed.

Other names: BR6001-1 + BR6001-2

Beyond the preview

Go deeper on BR6001-1 + BR6001-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR6001-1 + BR6001-2.

Explore the full profile